IPIX (Innovation Pharmaceuticals) Total Stockholders Equity: $1.16 Mil (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Innovation Pharmaceuticals Total Stockholders Equity?

Innovation Pharmaceuticals IPIX Total Stockholders Equity is $1.16 Mil as of Sep. 2023.

Innovation Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $1.16 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Innovation Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2023 was $0.00. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Innovation Pharmaceuticals's Debt-to-Equity for the quarter that ended in Sep. 2023 was 0.20.


Innovation Pharmaceuticals  (OTCPK:IPIX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Innovation Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2023 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Innovation Pharmaceuticals's Debt-to-Equity for the quarter that ended in Sep. 2023 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovation Pharmaceuticals Total Stockholders Equity Related Terms


Innovation Pharmaceuticals Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Innovation Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovation Pharmaceuticals Total Stockholders Equity Chart

Innovation Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.13 1.46 7.51 4.73 2.04

Innovation Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.42 3.08 2.72 2.04 1.16
What does a Total Stockholders Equity of $1.16 Mil mean?
Innovation Pharmaceuticals (IPIX) has a Total Stockholders Equity of $1.16 Mil as of Sep. 2023. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Innovation Pharmaceuticals and its competitors.
Is Innovation Pharmaceuticals' Total Stockholders Equity too high?
Innovation Pharmaceuticals' current Total Stockholders Equity is $1.16 Mil.
How does Innovation Pharmaceuticals' Total Stockholders Equity compare to AXIM and RNAZ?
Innovation Pharmaceuticals' Total Stockholders Equity of $1.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Innovation Pharmaceuticals and its competitors. Innovation Pharmaceuticals's current Total Stockholders Equity is $1.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovation Pharmaceuticals stock overvalued right now?
Innovation Pharmaceuticals (IPIX) has a current Total Stockholders Equity of $1.16 Mil. The current Total Stockholders Equity is $1.16 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Innovation Pharmaceuticals (IPIX), the current Total Stockholders Equity is $1.16 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innovation Pharmaceuticals Business Description

Address 301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.